Video Journal of Oncology (VJOncology)’s Post

One more day to the kickoff of PMWC - Precision Medicine World Conference 2024 in Silicon Valley ⏱ Join us to meet our passionate team and dive into the future of precision oncology with our CEO, Istvan Petak, MD, PhD. His talk on "Computational Method to Improve Treatment Decisions in Precision Oncology" is not to be missed! See you there? #PMWC24 #GenomateHealth #PrecisionOncology

Are you attending #EACR? Please make sure to stop by this important talk to learn more about #singlecell on our #DTCs #10xgenomics #discoverylifesciences #biospecimens #cellbiology #tumorcells #TILs

ICYMI: Watch the June Global Oncology Seminar Series with Dr. Beatrice Jepngetich presenting “Multiple Myeloma Care in Western Kenya, A Decade of Experience.” https://lnkd.in/gwvZwm2u

Check out the first meeting of the AI Community of Practice at American Society of Clinical Oncology (ASCO) - Ravi B. Parikh #AI #ClinicalOncology #ASCO24 #Cancer #OncoDaily #Oncology

Nice editorial out in Journal of Clinical Oncology on the design, analysis, and reporting of research that involves real-world data - Elisa Agostinetto #Cancer #JournalOfClinicalOncology #OncoDaily #Oncology

LBCA Scientific Advisory Board Chair, Dr. Jason Mouabbi, recently presented a research poster on invasive lobular carcinoma (ILC) at the American Society of Clinical Oncology (ASCO) annual meeting, one of the most significant gatherings of oncology professionals in the world. Dr. Mouabbi’s latest research reveals an evaluation approach that could lead to the development of personalized therapeutic strategies for ILC. See the poster and full abstract here: https://lnkd.in/ec7HUxcn #lobularbreastcancer #ilcresearch

Immunotherapy has transformed the endometrial cancer treatment landscape, particularly for those exhibiting mismatch repair deficiency [MMRd/microsatellite instability-hypermutated (MSI-H)]. A growing body of evidence supports the integration of immunotherapy with chemotherapy as a first-line treatment strategy. Recently, findings from ongoing trials such as RUBY (NCT03981796), NRG-GY018 (NCT03914612), AtTEnd (NCT03603184), and DUO-E (NCT04269200) have been disclosed. #clinicaltrials #endometrial #MSI #immunotherapy

An overview of the exciting genitourinary oncology data to come at ASCO24 - Karine Tawagi University of Illinois Chicago American Society of Clinical Oncology (ASCO) #ASCO24 #Cancer #GenitourinaryOncology #OncoDaily #Oncology

Post-SMR Congress, we asked Dr. Vernon Sondak what the Castle Biosciences Decision DX melanoma test could mean for patient testing. Here’s what he had to say. Don't miss out on the latest developments in oncology! Let us show you how we can get the insights you need from the experts you want to hear from. #OnvivExpertNetwork #SMR2024 #CongressInsights #Melanoma

Cancer EXPERT Now provides a benefit like nothing else. Members have access to the top Oncology influencers to inform on their case in an unbiased, agnostic manner. The peace of mind members need when facing the scariest news they’ve ever faced. To know you have choices, and you’ve heard it from the Top Expert in your cancer is empowering, and simply priceless. Our Experts are those all others look to for guidance. #benefits #healthinsurance #virtualcare #cancer